Thomas Bachelot
YOU?
Author Swipe
Remotely supervised online cognitive training to reduce cognitive difficulties following chemotherapy in patients treated for localized breast cancer: Protocol of the Cog-Stim2 multicenter randomized controlled trial Open
Introduction Chemotherapy-related cognitive impairment (CRCI) is frequently reported by breast cancer patients. Cognitive training is considered as one of the most effective approaches for improving cognitive function in patients with CRCI…
View article: Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data
Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data Open
Purpose: Despite current standard-of-care endocrine therapy, distant recurrence remains a concern for patients with hormone receptor–positive (HR+)/HER2− early breast cancer (EBC). Understanding individual recurrence risk would aid in clin…
View article: Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports
Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports Open
Background Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has demonstrated substantial clinical activity in metastatic HER2-positive breast cancer. Although durable res…
View article: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial Open
Antibody-drug conjugates have shown impressive clinical outcomes, particularly in metastatic breast cancer, but biomarkers to predict response and resistance remain unidentified. Here we report the results of ICARUS-BREAST01, a phase 2 stu…
View article: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay Open
PURPOSE Escalation of adjuvant systemic therapies (eg, with cyclin-dependent kinase 4 and 6 inhibitors) is now indicated for patients with clinically defined high-risk estrogen receptor–positive (ER+)/human epidermal growth factor receptor…
Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach Open
Breast cancer is characterized by genetic and epigenetic deregulations, leading to aberrant expression of tissue-specific genes that are normally silent in healthy breast tissue. Our previous work identified the embryonic stem cell-specifi…
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer Open
Novel selective estrogen receptor degraders (SERDs) are a promising therapeutic option under investigation for patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The effica…
View article: De Novo Oligometastatic Breast Cancer
De Novo Oligometastatic Breast Cancer Open
Metastatic breast cancer may present clinically either as recurrence after a previous diagnosis of stage I-III disease or as de novo metastatic breast cancer that is also called stage IV disease according to the American Joint Committee on…
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial Open
Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We report updated efficacy and safety analyses, including secondary and explo…
204P Clinical features predictive of never-progressive disease to first-line anti-HER2 therapy: Real-world data from the ESME national cohort Open
First-line (1L) anti-HER2 therapy has dramatically improved survival for patients (pts) with HER2+ metastatic breast cancer (MBC). We investigated clinicopathologic predictors of never progressive disease (PD) in the multicenter, real-worl…
Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature Open
The incidence of leptomeningeal metastases (LM) is increasing among breast cancer patients, but their prognosis remains dismal. Many therapeutic options are now available to treat HER2-positive (HER2+) metastatic breast cancer (MBC) involv…
De Novo Oligometastatic Breast Cancer Open
De novo oligometastatic breast cancer, a unique disease needing new treatment paradigms.
A Digital Solution for an Advanced Breast Tumor Board: Pilot Application Cocreation and Implementation Study Open
Background Cancer treatment is constantly evolving toward a more personalized approach based on clinical features, imaging, and genomic pathology information. To ensure the best care for patients, multidisciplinary teams (MDTs) meet regula…
View article: 121TiP LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early breast cancer at very low risk of metastasis
121TiP LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early breast cancer at very low risk of metastasis Open
Adjuvant Endocrine Therapy (AET) is the cornerstone treatment of localized hormone-receptor-positive (HR+) breast cancer, with demonstrated benefits on overall survival (30-40% relative decrease in mortality) but also on the risk of local …
View article: 214P Delphi consensus on the definition of visceral crisis in advanced breast cancer among French Breast Cancer Intergroup Unicancer (UCBG) experts
214P Delphi consensus on the definition of visceral crisis in advanced breast cancer among French Breast Cancer Intergroup Unicancer (UCBG) experts Open
CDK4/6 inhibitors combined with endocrine therapy have revolutionized the management of luminal advanced breast cancer (ABC). In case of visceral crisis (VC), chemotherapy is still recommended because of its supposed quicker efficacy. The …
193MO Development of a deep learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC) Open
Despite recent improvements in MBC management, sensitivity to treatment and disease outcomes remain heterogeneous. We developed a deep learning and user-friendly model to predict individual outcomes and select the most adequate treatments …